<DOC>
	<DOCNO>NCT02218879</DOCNO>
	<brief_summary>The primary objective directly estimate brain glutathione concentration vivo use H-MRS 7T initiation Tecfidera establish multiple sclerosis ( MS ) patient consider switch therapy treatment-naive ( first line ) .</brief_summary>
	<brief_title>Restoring Glutathione Synthesis With Tecfidera : An Vivo H-MRS Single-Arm Study 7T Patients With RR MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Male female adult patient 1860 year age Diagnosis multiple sclerosis , accordance revise McDonald criterion ( 2010 ) Patients naive MS therapy patient switch FDAapproved MS therapy , include IFNB formulation , Cop1 , Teriflunomide , Fingolimod BG12 Expanded Disability Status Scale ( EDSS ) score 0 5.5 inclusive Primary progressive multiple sclerosis patient Patients previous exposure know allergy fumarates MS patient switch natalizumab , cyclophosphamide , mitoxantrone BG12 Contraindications MRI/MRS Known presence neurological disorder may mimic multiple sclerosis Pregnancy lactation Requirement chronic treatment systemic corticosteroid immunosuppressant course study History currently active primary secondary immunodeficiency Active infection , history know presence recurrent chronic infection ( e.g . hepatitis B C , HIV , syphilis , tuberculosis_ History progressive multifocal leukoencephalopathy Contraindications intolerance oral intravenous ( IV ) corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>